Lipid risk factors and the regression of atherosclerosis

Antonio Gotto

doi:10.1016/S0002-9149(05)80009-8

Lipid risk factors and the regression of atherosclerosis

Antonio Gotto

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the progression of atherosclerosis may be slowed or even reversed. The clinical benefit observed in these trials strengthens the rationale for aggressive therapy in patients with known atherosclerotic disease. Additionally, these trials have provided further insight on the basis of clinical events and the risk factors associated with progression.

Original language	English (US)
Journal	The American Journal of Cardiology
Volume	76
Issue number	1-2 SUPPL. 1
DOIs	https://doi.org/10.1016/S0002-9149(05)80009-8
State	Published - Jul 13 1995

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/S0002-9149(05)80009-8

Cite this

@article{c43d31277da14a42a78f8eee8f007bb5,

title = "Lipid risk factors and the regression of atherosclerosis",

abstract = "Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the progression of atherosclerosis may be slowed or even reversed. The clinical benefit observed in these trials strengthens the rationale for aggressive therapy in patients with known atherosclerotic disease. Additionally, these trials have provided further insight on the basis of clinical events and the risk factors associated with progression.",

author = "Antonio Gotto",

year = "1995",

month = jul,

day = "13",

doi = "10.1016/S0002-9149(05)80009-8",

language = "English (US)",

volume = "76",

journal = "The American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier",

number = "1-2 SUPPL. 1",

}

TY - JOUR

T1 - Lipid risk factors and the regression of atherosclerosis

AU - Gotto, Antonio

PY - 1995/7/13

Y1 - 1995/7/13

N2 - Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the progression of atherosclerosis may be slowed or even reversed. The clinical benefit observed in these trials strengthens the rationale for aggressive therapy in patients with known atherosclerotic disease. Additionally, these trials have provided further insight on the basis of clinical events and the risk factors associated with progression.

AB - Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the progression of atherosclerosis may be slowed or even reversed. The clinical benefit observed in these trials strengthens the rationale for aggressive therapy in patients with known atherosclerotic disease. Additionally, these trials have provided further insight on the basis of clinical events and the risk factors associated with progression.

UR - http://www.scopus.com/inward/record.url?scp=0029040062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029040062&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(05)80009-8

DO - 10.1016/S0002-9149(05)80009-8

M3 - Article

C2 - 7604793

AN - SCOPUS:0029040062

SN - 0002-9149

VL - 76

JO - The American Journal of Cardiology

JF - The American Journal of Cardiology

IS - 1-2 SUPPL. 1

ER -

Lipid risk factors and the regression of atherosclerosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this